PREVIOUS
✖
mRNA Lung Cancer vaccine
August 31 , 2024
84 days
177
0
- The phase 1 trial for BNT116 is underway at 34 sites across seven countries, including the UK, US, and Germany.
- This is the world first mRNA-based lung cancer vaccine, developed by BioNTech.
- BNT116 aims to enable the immune system to target NSCLC tumour markers, attacking cancer cells while sparing healthy ones.
- Lung cancer is the top cause of cancer deaths worldwide, accounting for around 1.8 million deaths annually.
- mRNA (messenger RNA) is a molecule that contains the instructions or recipe that directs the cells to make a protein using its natural machinery.
Leave a Reply
Your Comment is awaiting moderation.